AU781674B2 - Novel antiarrhythmic peptides - Google Patents

Info

Publication number

AU781674B2

AU781674B2 AU35362/01A AU3536201A AU781674B2 AU 781674 B2 AU781674 B2 AU 781674B2 AU 35362/01 A AU35362/01 A AU 35362/01A AU 3536201 A AU3536201 A AU 3536201A AU 781674 B2 AU781674 B2 AU 781674B2

Authority

AU

Australia

Prior art keywords

sar

gly

pro

4hyp

ala

Prior art date

2000-02-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 108010082685 antiarrhythmic peptide Proteins 0.000 title description 15
• 150000001875 compounds Chemical class 0.000 claims abstract description 169
• 125000000539 amino acid group Chemical group 0.000 claims abstract description 33
• 150000003839 salts Chemical class 0.000 claims abstract description 33
• 125000001424 substituent group Chemical group 0.000 claims abstract description 12
• 229940125782 compound 2 Drugs 0.000 claims description 101
• 206010003119 arrhythmia Diseases 0.000 claims description 42
• 239000003814 drug Substances 0.000 claims description 38
• 206010047302 ventricular tachycardia Diseases 0.000 claims description 37
• 230000006793 arrhythmia Effects 0.000 claims description 36
• 238000002360 preparation method Methods 0.000 claims description 32
• 239000000203 mixture Substances 0.000 claims description 27
• 229910052736 halogen Inorganic materials 0.000 claims description 24
• 150000002367 halogens Chemical class 0.000 claims description 24
• 230000002829 reductive effect Effects 0.000 claims description 21
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 15
• 229910052739 hydrogen Inorganic materials 0.000 claims description 15
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 14
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 11
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 9
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 8
• 238000002347 injection Methods 0.000 claims description 7
• 239000007924 injection Substances 0.000 claims description 7
• 206010003658 Atrial Fibrillation Diseases 0.000 claims description 6
• 206010003671 Atrioventricular Block Diseases 0.000 claims description 5
• 208000003663 ventricular fibrillation Diseases 0.000 claims description 4
• 208000001871 Tachycardia Diseases 0.000 claims description 3
• 235000004279 alanine Nutrition 0.000 claims description 3
• 239000003085 diluting agent Substances 0.000 claims description 3
• 208000006218 bradycardia Diseases 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims description 2
• 241000894007 species Species 0.000 claims description 2
• 206010049447 Tachyarrhythmia Diseases 0.000 claims 2
• 206010049765 Bradyarrhythmia Diseases 0.000 claims 1
• 240000007594 Oryza sativa Species 0.000 claims 1
• 235000007164 Oryza sativa Nutrition 0.000 claims 1
• 235000009566 rice Nutrition 0.000 claims 1
• 108090000765 processed proteins & peptides Proteins 0.000 abstract description 281
• -1 aralkyl ester Chemical class 0.000 abstract description 131
• 239000000126 substance Substances 0.000 abstract description 50
• 125000003277 amino group Chemical group 0.000 abstract description 41
• 125000000217 alkyl group Chemical group 0.000 abstract description 28
• 125000003118 aryl group Chemical group 0.000 abstract description 25
• 150000001408 amides Chemical class 0.000 abstract description 16
• 125000004122 cyclic group Chemical group 0.000 abstract description 16
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 13
• 125000005647 linker group Chemical group 0.000 abstract description 8
• 101800001415 Bri23 peptide Proteins 0.000 abstract description 5
• 102400000107 C-terminal peptide Human genes 0.000 abstract description 5
• 101800000655 C-terminal peptide Proteins 0.000 abstract description 5
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 5
• 125000003710 aryl alkyl group Chemical group 0.000 abstract description 5
• 238000011191 terminal modification Methods 0.000 abstract description 4
• 101710188315 Protein X Proteins 0.000 abstract description 2
• 210000004027 cell Anatomy 0.000 description 226
• 238000005859 coupling reaction Methods 0.000 description 168
• 230000008878 coupling Effects 0.000 description 167
• 238000010168 coupling process Methods 0.000 description 167
• 239000011347 resin Substances 0.000 description 158
• 229920005989 resin Polymers 0.000 description 158
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 131
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 123
• 210000003976 gap junction Anatomy 0.000 description 120
• 108050001175 Connexin Proteins 0.000 description 106
• 102000010970 Connexin Human genes 0.000 description 105
• 239000000047 product Substances 0.000 description 91
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 89
• 238000010647 peptide synthesis reaction Methods 0.000 description 82
• 108010069241 Connexin 43 Proteins 0.000 description 81
• 102100021337 Gap junction alpha-1 protein Human genes 0.000 description 81
• 230000000694 effects Effects 0.000 description 77
• 238000012360 testing method Methods 0.000 description 64
• 239000000243 solution Substances 0.000 description 62
• 230000015572 biosynthetic process Effects 0.000 description 52
• 210000002216 heart Anatomy 0.000 description 51
• 238000000034 method Methods 0.000 description 50
• 238000002953 preparative HPLC Methods 0.000 description 45
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 44
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 44
• 239000004698 Polyethylene Substances 0.000 description 43
• 229920000573 polyethylene Polymers 0.000 description 43
• 239000004743 Polypropylene Substances 0.000 description 42
• 229920001155 polypropylene Polymers 0.000 description 42
• 238000000746 purification Methods 0.000 description 42
• 238000003786 synthesis reaction Methods 0.000 description 42
• 238000002474 experimental method Methods 0.000 description 40
• 238000001914 filtration Methods 0.000 description 40
• 238000010511 deprotection reaction Methods 0.000 description 39
• 230000001965 increasing effect Effects 0.000 description 39
• FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 39
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 37
• 210000001519 tissue Anatomy 0.000 description 37
• 230000010933 acylation Effects 0.000 description 36
• 238000005917 acylation reaction Methods 0.000 description 36
• 108010075130 AAP 10 Proteins 0.000 description 34
• 230000014509 gene expression Effects 0.000 description 34
• 235000002639 sodium chloride Nutrition 0.000 description 33
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 32
• 239000011575 calcium Substances 0.000 description 32
• 108091006146 Channels Proteins 0.000 description 31
• 235000001014 amino acid Nutrition 0.000 description 30
• 241000699670 Mus sp. Species 0.000 description 27
• 230000002861 ventricular Effects 0.000 description 27
• 230000004913 activation Effects 0.000 description 26
• 150000001413 amino acids Chemical class 0.000 description 26
• 230000001413 cellular effect Effects 0.000 description 26
• 102000004196 processed proteins & peptides Human genes 0.000 description 26
• 208000028867 ischemia Diseases 0.000 description 25
• 206010028980 Neoplasm Diseases 0.000 description 24
• 239000000975 dye Substances 0.000 description 24
• 230000007246 mechanism Effects 0.000 description 24
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 23
• 239000002253 acid Substances 0.000 description 23
• 125000003275 alpha amino acid group Chemical group 0.000 description 23
• 239000008103 glucose Substances 0.000 description 23
• 210000000963 osteoblast Anatomy 0.000 description 23
• 230000010412 perfusion Effects 0.000 description 23
• 230000000638 stimulation Effects 0.000 description 23
• 238000004891 communication Methods 0.000 description 22
• 230000006854 communication Effects 0.000 description 22
• 239000013058 crude material Substances 0.000 description 22
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 20
• 229910052791 calcium Inorganic materials 0.000 description 20
• 230000007423 decrease Effects 0.000 description 20
• 239000006185 dispersion Substances 0.000 description 20
• 230000002265 prevention Effects 0.000 description 20
• 229940079593 drug Drugs 0.000 description 19
• 230000006870 function Effects 0.000 description 19
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
• 239000002609 medium Substances 0.000 description 18
• 239000002904 solvent Substances 0.000 description 18
• 230000036982 action potential Effects 0.000 description 17
• 239000003416 antiarrhythmic agent Substances 0.000 description 17
• 230000000747 cardiac effect Effects 0.000 description 17
• 201000010099 disease Diseases 0.000 description 17
• 238000009826 distribution Methods 0.000 description 17
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 16
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 16
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 16
• 230000003247 decreasing effect Effects 0.000 description 16
• 230000006698 induction Effects 0.000 description 16
• DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 16
• 239000004471 Glycine Substances 0.000 description 15
• 210000004413 cardiac myocyte Anatomy 0.000 description 15
• 230000001582 osteoblastic effect Effects 0.000 description 15
• 108090000623 proteins and genes Proteins 0.000 description 15
• 241000282472 Canis lupus familiaris Species 0.000 description 14
• 101710177922 Gap junction alpha-5 protein Proteins 0.000 description 14
• 241000700159 Rattus Species 0.000 description 14
• 238000004458 analytical method Methods 0.000 description 14
• 230000003288 anthiarrhythmic effect Effects 0.000 description 14
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 14
• 230000033228 biological regulation Effects 0.000 description 14
• 239000003153 chemical reaction reagent Substances 0.000 description 14
• 238000011161 development Methods 0.000 description 14
• 230000001771 impaired effect Effects 0.000 description 14
• 229910052760 oxygen Inorganic materials 0.000 description 14
• 239000001301 oxygen Substances 0.000 description 14
• 239000002953 phosphate buffered saline Substances 0.000 description 14
• 230000027455 binding Effects 0.000 description 13
• 230000018109 developmental process Effects 0.000 description 13
• 238000001802 infusion Methods 0.000 description 13
• 230000035992 intercellular communication Effects 0.000 description 13
• 239000000523 sample Substances 0.000 description 13
• 238000012546 transfer Methods 0.000 description 13
• 206010011086 Coronary artery occlusion Diseases 0.000 description 12
• 102100030540 Gap junction alpha-5 protein Human genes 0.000 description 12
• 102100037260 Gap junction beta-1 protein Human genes 0.000 description 12
• 206010021143 Hypoxia Diseases 0.000 description 12
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 12
• 241000283973 Oryctolagus cuniculus Species 0.000 description 12
• 238000004128 high performance liquid chromatography Methods 0.000 description 12
• 238000000338 in vitro Methods 0.000 description 12
• 238000001727 in vivo Methods 0.000 description 12
• 230000004044 response Effects 0.000 description 12
• 230000007306 turnover Effects 0.000 description 12
• 230000002792 vascular Effects 0.000 description 12
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
• YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 11
• 208000027418 Wounds and injury Diseases 0.000 description 11
• 210000000988 bone and bone Anatomy 0.000 description 11
• 201000011510 cancer Diseases 0.000 description 11
• 229910052799 carbon Inorganic materials 0.000 description 11
• 230000003834 intracellular effect Effects 0.000 description 11
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
• 102000004169 proteins and genes Human genes 0.000 description 11
• 102100039290 Gap junction gamma-1 protein Human genes 0.000 description 10
• 101710178004 Gap junction gamma-1 protein Proteins 0.000 description 10
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 10
• 230000004075 alteration Effects 0.000 description 10
• 210000000709 aorta Anatomy 0.000 description 10
• 239000011324 bead Substances 0.000 description 10
• 230000012010 growth Effects 0.000 description 10
• 230000006609 metabolic stress Effects 0.000 description 10
• 230000011164 ossification Effects 0.000 description 10
• 239000008363 phosphate buffer Substances 0.000 description 10
• 235000018102 proteins Nutrition 0.000 description 10
• 102000005962 receptors Human genes 0.000 description 10
• 108020003175 receptors Proteins 0.000 description 10
• 210000002966 serum Anatomy 0.000 description 10
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 10
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
• 241001465754 Metazoa Species 0.000 description 9
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
• 208000001132 Osteoporosis Diseases 0.000 description 9
• 230000008859 change Effects 0.000 description 9
• 239000003795 chemical substances by application Substances 0.000 description 9
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 9
• 230000001684 chronic effect Effects 0.000 description 9
• 150000001923 cyclic compounds Chemical class 0.000 description 9
• 238000001514 detection method Methods 0.000 description 9
• 239000001963 growth medium Substances 0.000 description 9
• 229960000367 inositol Drugs 0.000 description 9
• 210000002569 neuron Anatomy 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 8
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 8
• 108010069514 Cyclic Peptides Proteins 0.000 description 8
• 102000001189 Cyclic Peptides Human genes 0.000 description 8
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 8
• 231100000504 carcinogenesis Toxicity 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• 238000003776 cleavage reaction Methods 0.000 description 8
• 230000037024 effective refractory period Effects 0.000 description 8
• 239000012530 fluid Substances 0.000 description 8
• 239000011521 glass Substances 0.000 description 8
• 230000035876 healing Effects 0.000 description 8
• 238000003384 imaging method Methods 0.000 description 8
• 230000001939 inductive effect Effects 0.000 description 8
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
• 210000004379 membrane Anatomy 0.000 description 8
• 239000012528 membrane Substances 0.000 description 8
• 230000002503 metabolic effect Effects 0.000 description 8
• 230000001105 regulatory effect Effects 0.000 description 8
• 230000002336 repolarization Effects 0.000 description 8
• 230000007017 scission Effects 0.000 description 8
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
• 230000035882 stress Effects 0.000 description 8
• 239000003981 vehicle Substances 0.000 description 8
• KSDTXRUIZMTBNV-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 KSDTXRUIZMTBNV-INIZCTEOSA-N 0.000 description 7
• 102100039104 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Human genes 0.000 description 7
• 206010019280 Heart failures Diseases 0.000 description 7
• 101000884921 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Proteins 0.000 description 7
• 108090000862 Ion Channels Proteins 0.000 description 7
• 102000004310 Ion Channels Human genes 0.000 description 7
• 108010029485 Protein Isoforms Proteins 0.000 description 7
• 102000001708 Protein Isoforms Human genes 0.000 description 7
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
• 206010052428 Wound Diseases 0.000 description 7
• 238000003287 bathing Methods 0.000 description 7
• 210000004899 c-terminal region Anatomy 0.000 description 7
• 230000015556 catabolic process Effects 0.000 description 7
• 210000000170 cell membrane Anatomy 0.000 description 7
• 238000006731 degradation reaction Methods 0.000 description 7
• 210000002837 heart atrium Anatomy 0.000 description 7
• 239000001257 hydrogen Substances 0.000 description 7
• 230000002218 hypoglycaemic effect Effects 0.000 description 7
• 210000004495 interstitial cells of cajal Anatomy 0.000 description 7
• 239000003446 ligand Substances 0.000 description 7
• 239000011777 magnesium Substances 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 229960002748 norepinephrine Drugs 0.000 description 7
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 7
• 230000011664 signaling Effects 0.000 description 7
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 7
• 239000007787 solid Substances 0.000 description 7
• 230000029663 wound healing Effects 0.000 description 7
• YQAXFVHNHSPUPO-RNJOBUHISA-N 2-[[(2s)-2-[[2-[[(2s,4r)-1-[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]propanoyl]amino]acetic acid Chemical class OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H]1N(C(=O)CN)CCC1 YQAXFVHNHSPUPO-RNJOBUHISA-N 0.000 description 6
• ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 6
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 6
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
• 208000005623 Carcinogenesis Diseases 0.000 description 6
• 101710202596 Gap junction beta-1 protein Proteins 0.000 description 6
• 206010020772 Hypertension Diseases 0.000 description 6
• 241000219739 Lens Species 0.000 description 6
• 208000007107 Stomach Ulcer Diseases 0.000 description 6
• 230000002159 abnormal effect Effects 0.000 description 6
• 230000003213 activating effect Effects 0.000 description 6
• 229960001456 adenosine triphosphate Drugs 0.000 description 6
• 230000001746 atrial effect Effects 0.000 description 6
• 210000002449 bone cell Anatomy 0.000 description 6
• 230000036952 cancer formation Effects 0.000 description 6
• 238000004113 cell culture Methods 0.000 description 6
• 125000004093 cyano group Chemical group *C#N 0.000 description 6
• 230000006378 damage Effects 0.000 description 6
• 230000002950 deficient Effects 0.000 description 6
• 235000014113 dietary fatty acids Nutrition 0.000 description 6
• 230000003828 downregulation Effects 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 239000000194 fatty acid Substances 0.000 description 6
• 229930195729 fatty acid Natural products 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 238000011534 incubation Methods 0.000 description 6
• 238000001990 intravenous administration Methods 0.000 description 6
• 229910052740 iodine Inorganic materials 0.000 description 6
• 150000002500 ions Chemical class 0.000 description 6
• 238000002372 labelling Methods 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 208000031225 myocardial ischemia Diseases 0.000 description 6
• 210000000287 oocyte Anatomy 0.000 description 6
• 230000035699 permeability Effects 0.000 description 6
• 230000026731 phosphorylation Effects 0.000 description 6
• 238000006366 phosphorylation reaction Methods 0.000 description 6
• 230000009467 reduction Effects 0.000 description 6
• 239000011734 sodium Substances 0.000 description 6
• 230000002269 spontaneous effect Effects 0.000 description 6
• 230000002459 sustained effect Effects 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
• 208000002177 Cataract Diseases 0.000 description 5
• 241000700199 Cavia porcellus Species 0.000 description 5
• 102000029816 Collagenase Human genes 0.000 description 5
• 108060005980 Collagenase Proteins 0.000 description 5
• 102100037156 Gap junction beta-2 protein Human genes 0.000 description 5
• 101710198067 Gap junction beta-2 protein Proteins 0.000 description 5
• 208000013016 Hypoglycemia Diseases 0.000 description 5
• 108090001061 Insulin Proteins 0.000 description 5
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
• 229930182555 Penicillin Natural products 0.000 description 5
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
• 230000009471 action Effects 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 210000001612 chondrocyte Anatomy 0.000 description 5
• 229960002424 collagenase Drugs 0.000 description 5
• 229940126214 compound 3 Drugs 0.000 description 5
• 108010015416 connexin 32 Proteins 0.000 description 5
• 230000003205 diastolic effect Effects 0.000 description 5
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
• 150000004665 fatty acids Chemical class 0.000 description 5
• 210000002503 granulosa cell Anatomy 0.000 description 5
• 208000019622 heart disease Diseases 0.000 description 5
• 125000001072 heteroaryl group Chemical group 0.000 description 5
• 230000007954 hypoxia Effects 0.000 description 5
• 230000001146 hypoxic effect Effects 0.000 description 5
• 238000011065 in-situ storage Methods 0.000 description 5
• 239000003112 inhibitor Substances 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 239000010410 layer Substances 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 230000033001 locomotion Effects 0.000 description 5
• 238000004519 manufacturing process Methods 0.000 description 5
• 238000013507 mapping Methods 0.000 description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
• 229910052757 nitrogen Inorganic materials 0.000 description 5
• 210000000056 organ Anatomy 0.000 description 5
• 230000001590 oxidative effect Effects 0.000 description 5
• 229940049954 penicillin Drugs 0.000 description 5
• 230000002441 reversible effect Effects 0.000 description 5
• 230000019491 signal transduction Effects 0.000 description 5
• 239000002356 single layer Substances 0.000 description 5
• 239000000717 tumor promoter Substances 0.000 description 5
• UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 4
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
• 206010002091 Anaesthesia Diseases 0.000 description 4
• 206010011878 Deafness Diseases 0.000 description 4
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
• 206010061216 Infarction Diseases 0.000 description 4
• 102000004877 Insulin Human genes 0.000 description 4
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
• 108700020796 Oncogene Proteins 0.000 description 4
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
• ONPXCLZMBSJLSP-CSMHCCOUSA-N Pro-Hyp Chemical compound C1[C@H](O)C[C@@H](C(O)=O)N1C(=O)[C@H]1NCCC1 ONPXCLZMBSJLSP-CSMHCCOUSA-N 0.000 description 4
• 206010042434 Sudden death Diseases 0.000 description 4
• 208000007536 Thrombosis Diseases 0.000 description 4
• 208000025865 Ulcer Diseases 0.000 description 4
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
• 229960004373 acetylcholine Drugs 0.000 description 4
• 230000037005 anaesthesia Effects 0.000 description 4
• 150000008064 anhydrides Chemical class 0.000 description 4
• 230000002785 anti-thrombosis Effects 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 210000001130 astrocyte Anatomy 0.000 description 4
• 239000012298 atmosphere Substances 0.000 description 4
• 230000002238 attenuated effect Effects 0.000 description 4
• 210000003403 autonomic nervous system Anatomy 0.000 description 4
• 210000003050 axon Anatomy 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 210000004556 brain Anatomy 0.000 description 4
• 125000004432 carbon atom Chemical group C* 0.000 description 4
• 210000000845 cartilage Anatomy 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 239000012043 crude product Substances 0.000 description 4
• 210000000805 cytoplasm Anatomy 0.000 description 4
• 230000001086 cytosolic effect Effects 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 4
• 230000007515 enzymatic degradation Effects 0.000 description 4
• 210000002919 epithelial cell Anatomy 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• 230000005284 excitation Effects 0.000 description 4
• 239000000835 fiber Substances 0.000 description 4
• 239000000706 filtrate Substances 0.000 description 4
• 208000016354 hearing loss disease Diseases 0.000 description 4
• 229960002897 heparin Drugs 0.000 description 4
• 229920000669 heparin Polymers 0.000 description 4
• 229940088597 hormone Drugs 0.000 description 4
• 239000005556 hormone Substances 0.000 description 4
• 229960002591 hydroxyproline Drugs 0.000 description 4
• 230000007574 infarction Effects 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 208000014674 injury Diseases 0.000 description 4
• 229940125396 insulin Drugs 0.000 description 4
• 210000005240 left ventricle Anatomy 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 230000004060 metabolic process Effects 0.000 description 4
• 238000000520 microinjection Methods 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• 230000002107 myocardial effect Effects 0.000 description 4
• CHVZPRDGLWBEMJ-UHFFFAOYSA-N n-chlorobenzenesulfonamide Chemical compound ClNS(=O)(=O)C1=CC=CC=C1 CHVZPRDGLWBEMJ-UHFFFAOYSA-N 0.000 description 4
• 210000001672 ovary Anatomy 0.000 description 4
• 230000001575 pathological effect Effects 0.000 description 4
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
• 229910052700 potassium Inorganic materials 0.000 description 4
• 239000011591 potassium Substances 0.000 description 4
• 230000002028 premature Effects 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
• 230000002285 radioactive effect Effects 0.000 description 4
• 238000011084 recovery Methods 0.000 description 4
• 230000033764 rhythmic process Effects 0.000 description 4
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
• 230000007480 spreading Effects 0.000 description 4
• 238000003892 spreading Methods 0.000 description 4
• 229960005322 streptomycin Drugs 0.000 description 4
• 230000014616 translation Effects 0.000 description 4
• 231100000397 ulcer Toxicity 0.000 description 4
• 230000006498 vasomotor response Effects 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
• TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• 208000026310 Breast neoplasm Diseases 0.000 description 3
• BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 3
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
• 206010007559 Cardiac failure congestive Diseases 0.000 description 3
• 229940126639 Compound 33 Drugs 0.000 description 3
• 150000008574 D-amino acids Chemical group 0.000 description 3
• OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical group OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 3
• 208000007984 Female Infertility Diseases 0.000 description 3
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
• 206010021928 Infertility female Diseases 0.000 description 3
• 208000012659 Joint disease Diseases 0.000 description 3
• 239000012839 Krebs-Henseleit buffer Substances 0.000 description 3
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
• 102000043276 Oncogene Human genes 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
• RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 3
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical group OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 102000001253 Protein Kinase Human genes 0.000 description 3
• PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• 206010047281 Ventricular arrhythmia Diseases 0.000 description 3
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
• PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 3
• 125000003342 alkenyl group Chemical group 0.000 description 3
• 238000001949 anaesthesia Methods 0.000 description 3
• 230000002763 arrhythmic effect Effects 0.000 description 3
• 210000001367 artery Anatomy 0.000 description 3
• 230000004888 barrier function Effects 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 210000001185 bone marrow Anatomy 0.000 description 3
• 229910052794 bromium Inorganic materials 0.000 description 3
• 230000005587 bubbling Effects 0.000 description 3
• 239000007853 buffer solution Substances 0.000 description 3
• 229910001424 calcium ion Inorganic materials 0.000 description 3
• 150000001721 carbon Chemical group 0.000 description 3
• 210000005242 cardiac chamber Anatomy 0.000 description 3
• 230000008568 cell cell communication Effects 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 210000000038 chest Anatomy 0.000 description 3
• 230000000052 comparative effect Effects 0.000 description 3
• 229940125904 compound 1 Drugs 0.000 description 3
• 229940126086 compound 21 Drugs 0.000 description 3
• 229940125851 compound 27 Drugs 0.000 description 3
• 229940125877 compound 31 Drugs 0.000 description 3
• 231100000895 deafness Toxicity 0.000 description 3
• 230000006735 deficit Effects 0.000 description 3
• 238000006073 displacement reaction Methods 0.000 description 3
• 208000000718 duodenal ulcer Diseases 0.000 description 3
• 238000011067 equilibration Methods 0.000 description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
• 229910052731 fluorine Inorganic materials 0.000 description 3
• 229940028334 follicle stimulating hormone Drugs 0.000 description 3
• YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 3
• 230000002496 gastric effect Effects 0.000 description 3
• 210000001156 gastric mucosa Anatomy 0.000 description 3
• 201000005917 gastric ulcer Diseases 0.000 description 3
• 230000002518 glial effect Effects 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 230000013632 homeostatic process Effects 0.000 description 3
• 235000003642 hunger Nutrition 0.000 description 3
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
• 230000000396 hypokalemic effect Effects 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 210000000936 intestine Anatomy 0.000 description 3
• 210000004153 islets of langerhan Anatomy 0.000 description 3
• 238000011813 knockout mouse model Methods 0.000 description 3
• 231100000518 lethal Toxicity 0.000 description 3
• 230000001665 lethal effect Effects 0.000 description 3
• 229910052749 magnesium Inorganic materials 0.000 description 3
• 239000002207 metabolite Substances 0.000 description 3
• DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 3
• 229960003793 midazolam Drugs 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 239000003607 modifier Substances 0.000 description 3
• 210000004165 myocardium Anatomy 0.000 description 3
• 210000000754 myometrium Anatomy 0.000 description 3
• 230000001537 neural effect Effects 0.000 description 3
• 125000004433 nitrogen atom Chemical group N* 0.000 description 3
• 235000015097 nutrients Nutrition 0.000 description 3
• 230000016087 ovulation Effects 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 230000004962 physiological condition Effects 0.000 description 3
• 239000011148 porous material Substances 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 238000002203 pretreatment Methods 0.000 description 3
• 230000001536 pro-arrhythmogenic effect Effects 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 230000002035 prolonged effect Effects 0.000 description 3
• 108010077112 prolyl-proline Proteins 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 230000000644 propagated effect Effects 0.000 description 3
• 108060006633 protein kinase Proteins 0.000 description 3
• 235000021251 pulses Nutrition 0.000 description 3
• 230000001603 reducing effect Effects 0.000 description 3
• 238000005070 sampling Methods 0.000 description 3
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
• 210000001013 sinoatrial node Anatomy 0.000 description 3
• 210000000813 small intestine Anatomy 0.000 description 3
• 210000002460 smooth muscle Anatomy 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 3
• 229960002370 sotalol Drugs 0.000 description 3
• 230000009870 specific binding Effects 0.000 description 3
• 230000037351 starvation Effects 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 229910052717 sulfur Inorganic materials 0.000 description 3
• 230000001360 synchronised effect Effects 0.000 description 3
• 210000001550 testis Anatomy 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 210000004881 tumor cell Anatomy 0.000 description 3
• 238000011144 upstream manufacturing Methods 0.000 description 3
• 210000004291 uterus Anatomy 0.000 description 3
• QYYZXEPEVBXNNA-QGZVFWFLSA-N (1R)-2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound C(C)(=O)N1[C@H](C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)O QYYZXEPEVBXNNA-QGZVFWFLSA-N 0.000 description 2
• ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
• AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
• CCVYRRGZDBSHFU-UHFFFAOYSA-N (2-hydroxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1O CCVYRRGZDBSHFU-UHFFFAOYSA-N 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
• UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
• HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
• PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
• XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 description 2
• KKADPXVIOXHVKN-UHFFFAOYSA-N 4-hydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C=C1 KKADPXVIOXHVKN-UHFFFAOYSA-N 0.000 description 2
• HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
• ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 2
• 206010002660 Anoxia Diseases 0.000 description 2
• 241000976983 Anoxia Species 0.000 description 2
• 208000019901 Anxiety disease Diseases 0.000 description 2
• 235000021357 Behenic acid Nutrition 0.000 description 2
• 208000006386 Bone Resorption Diseases 0.000 description 2
• 208000020084 Bone disease Diseases 0.000 description 2
• 206010065687 Bone loss Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 206010006578 Bundle-Branch Block Diseases 0.000 description 2
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
• 108090000312 Calcium Channels Proteins 0.000 description 2
• 102000003922 Calcium Channels Human genes 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 208000031229 Cardiomyopathies Diseases 0.000 description 2
• 229940126657 Compound 17 Drugs 0.000 description 2
• 229940127007 Compound 39 Drugs 0.000 description 2
• 102000014824 Crystallins Human genes 0.000 description 2
• 108010064003 Crystallins Proteins 0.000 description 2
• 229920000858 Cyclodextrin Polymers 0.000 description 2
• ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 2
• 229930195709 D-tyrosine Natural products 0.000 description 2
• 125000002849 D-tyrosine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 2
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
• 102000009123 Fibrin Human genes 0.000 description 2
• 108010073385 Fibrin Proteins 0.000 description 2
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
• 102100030525 Gap junction alpha-4 protein Human genes 0.000 description 2
• 101710190724 Gap junction alpha-4 protein Proteins 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• 208000004547 Hallucinations Diseases 0.000 description 2
• 206010019695 Hepatic neoplasm Diseases 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 238000012404 In vitro experiment Methods 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 150000008575 L-amino acids Chemical group 0.000 description 2
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
• 102000009151 Luteinizing Hormone Human genes 0.000 description 2
• 108010073521 Luteinizing Hormone Proteins 0.000 description 2
• 102000043136 MAP kinase family Human genes 0.000 description 2
• 108091054455 MAP kinase family Proteins 0.000 description 2
• 208000007466 Male Infertility Diseases 0.000 description 2
• YPIQVCUJEKAZCP-UHFFFAOYSA-N Malotilate Chemical compound CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 YPIQVCUJEKAZCP-UHFFFAOYSA-N 0.000 description 2
• 108010052285 Membrane Proteins Proteins 0.000 description 2
• 208000026139 Memory disease Diseases 0.000 description 2
• 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
• 102000004067 Osteocalcin Human genes 0.000 description 2
• 108090000573 Osteocalcin Proteins 0.000 description 2
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
• 208000028017 Psychotic disease Diseases 0.000 description 2
• 108010080192 Purinergic Receptors Proteins 0.000 description 2
• 102000000033 Purinergic Receptors Human genes 0.000 description 2
• 241000700157 Rattus norvegicus Species 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 108010052164 Sodium Channels Proteins 0.000 description 2
• 102000018674 Sodium Channels Human genes 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 208000007718 Stable Angina Diseases 0.000 description 2
• 206010049418 Sudden Cardiac Death Diseases 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 241000223109 Trypanosoma cruzi Species 0.000 description 2
• 208000007814 Unstable Angina Diseases 0.000 description 2
• SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
• SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
• 210000003489 abdominal muscle Anatomy 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 125000002252 acyl group Chemical group 0.000 description 2
• UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
• 230000004520 agglutination Effects 0.000 description 2
• 150000001335 aliphatic alkanes Chemical class 0.000 description 2
• 150000001447 alkali salts Chemical class 0.000 description 2
• 125000003545 alkoxy group Chemical group 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 229940093740 amino acid and derivative Drugs 0.000 description 2
• 229960005260 amiodarone Drugs 0.000 description 2
• 230000003444 anaesthetic effect Effects 0.000 description 2
• 230000007953 anoxia Effects 0.000 description 2
• 230000036506 anxiety Effects 0.000 description 2
• 230000004872 arterial blood pressure Effects 0.000 description 2
• 210000002565 arteriole Anatomy 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 125000004104 aryloxy group Chemical group 0.000 description 2
• XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 210000001992 atrioventricular node Anatomy 0.000 description 2
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• 229940116226 behenic acid Drugs 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical group NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
• 230000008827 biological function Effects 0.000 description 2
• 230000005540 biological transmission Effects 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 230000036770 blood supply Effects 0.000 description 2
• 230000024279 bone resorption Effects 0.000 description 2
• 210000004375 bundle of his Anatomy 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 244000309466 calf Species 0.000 description 2
• UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 229940125797 compound 12 Drugs 0.000 description 2
• 229940126543 compound 14 Drugs 0.000 description 2
• 229940125961 compound 24 Drugs 0.000 description 2
• 229940126540 compound 41 Drugs 0.000 description 2
• 229940125936 compound 42 Drugs 0.000 description 2
• 229940125844 compound 46 Drugs 0.000 description 2
• 229940127271 compound 49 Drugs 0.000 description 2
• 239000012141 concentrate Substances 0.000 description 2
• 235000008504 concentrate Nutrition 0.000 description 2
• 230000008602 contraction Effects 0.000 description 2
• 210000004087 cornea Anatomy 0.000 description 2
• 210000004351 coronary vessel Anatomy 0.000 description 2
• 210000004246 corpus luteum Anatomy 0.000 description 2
• 238000012937 correction Methods 0.000 description 2
• 230000001054 cortical effect Effects 0.000 description 2
• 210000004748 cultured cell Anatomy 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 238000000586 desensitisation Methods 0.000 description 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
• 229960003957 dexamethasone Drugs 0.000 description 2
• 150000008049 diazo compounds Chemical class 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 238000009792 diffusion process Methods 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 239000012153 distilled water Substances 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 210000004242 electrical synapse Anatomy 0.000 description 2
• 210000002257 embryonic structure Anatomy 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 230000003511 endothelial effect Effects 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
• 229960004207 fentanyl citrate Drugs 0.000 description 2
• 239000012894 fetal calf serum Substances 0.000 description 2
• 229950003499 fibrin Drugs 0.000 description 2
• 230000003325 follicular Effects 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 230000007946 glucose deprivation Effects 0.000 description 2
• 125000005843 halogen group Chemical group 0.000 description 2
• 238000003306 harvesting Methods 0.000 description 2
• 210000005003 heart tissue Anatomy 0.000 description 2
• 230000023597 hemostasis Effects 0.000 description 2
• 210000003494 hepatocyte Anatomy 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 2
• 239000011261 inert gas Substances 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 238000006713 insertion reaction Methods 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• 229940044173 iodine-125 Drugs 0.000 description 2
• 230000000302 ischemic effect Effects 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• 208000014018 liver neoplasm Diseases 0.000 description 2
• RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 208000004731 long QT syndrome Diseases 0.000 description 2
• 210000003141 lower extremity Anatomy 0.000 description 2
• 229940040129 luteinizing hormone Drugs 0.000 description 2
• XDOFWFNMYJRHEW-UHFFFAOYSA-N m-hydroxyhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(O)=C1 XDOFWFNMYJRHEW-UHFFFAOYSA-N 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 229950000470 malotilate Drugs 0.000 description 2
• 230000035800 maturation Effects 0.000 description 2
• 230000021121 meiosis Effects 0.000 description 2
• 230000028161 membrane depolarization Effects 0.000 description 2
• 206010027175 memory impairment Diseases 0.000 description 2
• 230000005012 migration Effects 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
• 230000004899 motility Effects 0.000 description 2
• 230000004118 muscle contraction Effects 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 230000010309 neoplastic transformation Effects 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 239000012299 nitrogen atmosphere Substances 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 230000009871 nonspecific binding Effects 0.000 description 2
• 230000007959 normoxia Effects 0.000 description 2
• 230000002246 oncogenic effect Effects 0.000 description 2
• 210000003463 organelle Anatomy 0.000 description 2
• 230000010355 oscillation Effects 0.000 description 2
• LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 2
• 230000002611 ovarian Effects 0.000 description 2
• 210000002394 ovarian follicle Anatomy 0.000 description 2
• 210000003540 papillary muscle Anatomy 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 208000003013 permanent neonatal diabetes mellitus Diseases 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
• 229960002695 phenobarbital Drugs 0.000 description 2
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
• LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 2
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 238000005222 photoaffinity labeling Methods 0.000 description 2
• 238000006303 photolysis reaction Methods 0.000 description 2
• 230000015843 photosynthesis, light reaction Effects 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 238000000159 protein binding assay Methods 0.000 description 2
• 230000036279 refractory period Effects 0.000 description 2
• 230000008439 repair process Effects 0.000 description 2
• 230000001850 reproductive effect Effects 0.000 description 2
• 230000004043 responsiveness Effects 0.000 description 2
• 210000005241 right ventricle Anatomy 0.000 description 2
• 108010054669 rotigaptide Proteins 0.000 description 2
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 229940054269 sodium pyruvate Drugs 0.000 description 2
• YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 2
• 229910001220 stainless steel Inorganic materials 0.000 description 2
• 239000010935 stainless steel Substances 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 210000001562 sternum Anatomy 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• CYFLXLSBHQBMFT-UHFFFAOYSA-N sulfamoxole Chemical group O1C(C)=C(C)N=C1NS(=O)(=O)C1=CC=C(N)C=C1 CYFLXLSBHQBMFT-UHFFFAOYSA-N 0.000 description 2
• 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 2
• 239000011593 sulfur Chemical group 0.000 description 2
• 230000008093 supporting effect Effects 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 210000000115 thoracic cavity Anatomy 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 230000004865 vascular response Effects 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• 102000009310 vitamin D receptors Human genes 0.000 description 2
• 108050000156 vitamin D receptors Proteins 0.000 description 2
• 208000020294 von Willebrand disease 1 Diseases 0.000 description 2
• UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
• ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
• GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
• SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
• BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
• GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
• IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
• WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
• STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
• HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
• QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
• IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
• YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
• DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
• LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical class OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
• ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
• UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
• XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
• WSNDAYQNZRJGMJ-UHFFFAOYSA-N 2,2,2-trifluoroethanone Chemical compound FC(F)(F)[C]=O WSNDAYQNZRJGMJ-UHFFFAOYSA-N 0.000 description 1
• LPXHPAYRONCQIF-UHFFFAOYSA-N 2-(2-hydroxyphenoxy)acetic acid Chemical compound OC(=O)COC1=CC=CC=C1O LPXHPAYRONCQIF-UHFFFAOYSA-N 0.000 description 1
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
• OQMYZVWIXPPDDE-UHFFFAOYSA-N 2-(cyclohexylazaniumyl)acetate Chemical group OC(=O)CNC1CCCCC1 OQMYZVWIXPPDDE-UHFFFAOYSA-N 0.000 description 1
• VUCNQOPCYRJCGQ-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenoxy]acetic acid Chemical compound OCC1=CC=C(OCC(O)=O)C=C1 VUCNQOPCYRJCGQ-UHFFFAOYSA-N 0.000 description 1
• YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
• DPNFPNYMPUQQRZ-UHFFFAOYSA-N 2-azidooxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1ON=[N+]=[N-] DPNFPNYMPUQQRZ-UHFFFAOYSA-N 0.000 description 1
• FVMDYYGIDFPZAX-UHFFFAOYSA-N 3-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=CC(O)=C1 FVMDYYGIDFPZAX-UHFFFAOYSA-N 0.000 description 1
• CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
• PKGWLCZTTHWKIZ-UHFFFAOYSA-N 4-Hydroxypheoxyacetate Chemical compound OC(=O)COC1=CC=C(O)C=C1 PKGWLCZTTHWKIZ-UHFFFAOYSA-N 0.000 description 1
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
• 101800000263 Acidic protein Proteins 0.000 description 1
• LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
• 229910002012 Aerosil® Inorganic materials 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 238000008940 Alkaline Phosphatase assay kit Methods 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010001935 American trypanosomiasis Diseases 0.000 description 1
• APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 101100441312 Arabidopsis thaliana CST gene Proteins 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 208000002102 Atrial Premature Complexes Diseases 0.000 description 1
• 206010003662 Atrial flutter Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 208000010392 Bone Fractures Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 102400000967 Bradykinin Human genes 0.000 description 1
• 101800004538 Bradykinin Proteins 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
• KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 206010048610 Cardiotoxicity Diseases 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 208000024699 Chagas disease Diseases 0.000 description 1
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
• OJYGBLRPYBAHRT-OPKHMCHVSA-N Chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H](C(O)CO)OC21 OJYGBLRPYBAHRT-OPKHMCHVSA-N 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 208000002330 Congenital Heart Defects Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 208000027205 Congenital disease Diseases 0.000 description 1
• 206010010539 Congenital megacolon Diseases 0.000 description 1
• 206010062346 Congenital neuropathy Diseases 0.000 description 1
• 201000006306 Cor pulmonale Diseases 0.000 description 1
• 206010011026 Corneal lesion Diseases 0.000 description 1
• 208000014311 Cushing syndrome Diseases 0.000 description 1
• 206010011732 Cyst Diseases 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 101100329834 Danio rerio gja1 gene Proteins 0.000 description 1
• 208000033986 Device capturing issue Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• 208000006402 Ductal Carcinoma Diseases 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 108010056764 Eptifibatide Proteins 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 206010063560 Excessive granulation tissue Diseases 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 206010016803 Fluid overload Diseases 0.000 description 1
• 102000020897 Formins Human genes 0.000 description 1
• 108091022623 Formins Proteins 0.000 description 1
• 102100030526 Gap junction alpha-3 protein Human genes 0.000 description 1
• 101710198379 Gap junction alpha-3 protein Proteins 0.000 description 1
• 102100039397 Gap junction beta-3 protein Human genes 0.000 description 1
• 101710082451 Gap junction beta-3 protein Proteins 0.000 description 1
• 102100039401 Gap junction beta-6 protein Human genes 0.000 description 1
• 101710188943 Gap junction beta-6 protein Proteins 0.000 description 1
• 102100025623 Gap junction delta-2 protein Human genes 0.000 description 1
• 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 241000948258 Gila Species 0.000 description 1
• UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
• GGEJHJIXRBTJPD-BYPYZUCNSA-N Gly-Asn-Gly Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GGEJHJIXRBTJPD-BYPYZUCNSA-N 0.000 description 1
• LURCIJSJAKFCRO-QWRGUYRKSA-N Gly-Asn-Tyr Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LURCIJSJAKFCRO-QWRGUYRKSA-N 0.000 description 1
• VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 1
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
• 239000012630 HPLC buffer Substances 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 208000004592 Hirschsprung disease Diseases 0.000 description 1
• 101100276172 Homo sapiens GJB1 gene Proteins 0.000 description 1
• 101000616432 Homo sapiens Microtubule-associated protein 6 Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 208000019025 Hypokalemia Diseases 0.000 description 1
• 210000002370 ICC Anatomy 0.000 description 1
• 208000035901 Ischaemic ulcer Diseases 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 208000002720 Malnutrition Diseases 0.000 description 1
• 208000029725 Metabolic bone disease Diseases 0.000 description 1
• 108090001040 Microtubule-associated protein 1B Proteins 0.000 description 1
• 102000004866 Microtubule-associated protein 1B Human genes 0.000 description 1
• 102100021791 Microtubule-associated protein 6 Human genes 0.000 description 1
• 108700005084 Multigene Family Proteins 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 101000894982 Mus musculus Gap junction alpha-1 protein Proteins 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 108010079364 N-glycylalanine Proteins 0.000 description 1
• NPKSPKHJBVJUKB-UHFFFAOYSA-N N-phenylglycine Chemical compound OC(=O)CNC1=CC=CC=C1 NPKSPKHJBVJUKB-UHFFFAOYSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 208000028389 Nerve injury Diseases 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
• LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
• 102400000050 Oxytocin Human genes 0.000 description 1
• XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
• 101800000989 Oxytocin Proteins 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
• 108010035030 Platelet Membrane Glycoprotein IIb Proteins 0.000 description 1
• 229920000361 Poly(styrene)-block-poly(ethylene glycol) Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 102000004257 Potassium Channel Human genes 0.000 description 1
• 102100025803 Progesterone receptor Human genes 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 208000010378 Pulmonary Embolism Diseases 0.000 description 1
• 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
• 206010037419 Pulmonary malformation Diseases 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 108010077895 Sarcosine Proteins 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 208000001770 Sinoatrial Nodal Reentry Tachycardia Diseases 0.000 description 1
• 206010040741 Sinus bradycardia Diseases 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 244000166550 Strophanthus gratus Species 0.000 description 1
• 208000003734 Supraventricular Tachycardia Diseases 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 208000018452 Torsade de pointes Diseases 0.000 description 1
• 208000002363 Torsades de Pointes Diseases 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 241000223104 Trypanosoma Species 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
• 229930003316 Vitamin D Natural products 0.000 description 1
• 241001433070 Xiphoides Species 0.000 description 1
• MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
• LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
• LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
• PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
• 229960000446 abciximab Drugs 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 206010000891 acute myocardial infarction Diseases 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 229960002648 alanylglutamine Drugs 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
• 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• 150000005215 alkyl ethers Chemical class 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 150000003862 amino acid derivatives Chemical class 0.000 description 1
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
• 229960003942 amphotericin b Drugs 0.000 description 1
• 229940124326 anaesthetic agent Drugs 0.000 description 1
• 210000003484 anatomy Anatomy 0.000 description 1
• 238000005571 anion exchange chromatography Methods 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 229940124350 antibacterial drug Drugs 0.000 description 1
• 229940125715 antihistaminic agent Drugs 0.000 description 1
• 239000000739 antihistaminic agent Substances 0.000 description 1
• 239000003699 antiulcer agent Substances 0.000 description 1
• 206010002906 aortic stenosis Diseases 0.000 description 1
• 210000001765 aortic valve Anatomy 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 210000001188 articular cartilage Anatomy 0.000 description 1
• 230000001174 ascending effect Effects 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 210000001008 atrial appendage Anatomy 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 230000002567 autonomic effect Effects 0.000 description 1
• 239000003855 balanced salt solution Substances 0.000 description 1
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
• 238000010009 beating Methods 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
• 239000012965 benzophenone Substances 0.000 description 1
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
• 229940000635 beta-alanine Drugs 0.000 description 1
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
• JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 239000001045 blue dye Substances 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 230000037182 bone density Effects 0.000 description 1
• 230000014461 bone development Effects 0.000 description 1
• 210000002805 bone matrix Anatomy 0.000 description 1
• 230000008416 bone turnover Effects 0.000 description 1
• 239000005388 borosilicate glass Substances 0.000 description 1
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 230000002308 calcification Effects 0.000 description 1
• 230000003317 calciotropic effect Effects 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• 231100000357 carcinogen Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 206010061592 cardiac fibrillation Diseases 0.000 description 1
• 231100000259 cardiotoxicity Toxicity 0.000 description 1
• 230000007681 cardiovascular toxicity Effects 0.000 description 1
• 230000022159 cartilage development Effects 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 150000003943 catecholamines Chemical class 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 239000013553 cell monolayer Substances 0.000 description 1
• 230000009134 cell regulation Effects 0.000 description 1
• 230000023549 cell-cell signaling Effects 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 230000030570 cellular localization Effects 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 230000002113 chemopreventative effect Effects 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 150000001805 chlorine compounds Chemical class 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• 230000002057 chronotropic effect Effects 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• BJBUEDPLEOHJGE-IUYQGCFVSA-N cis-3-hydroxy-D-proline zwitterion Chemical compound O[C@H]1CCN[C@H]1C(O)=O BJBUEDPLEOHJGE-IUYQGCFVSA-N 0.000 description 1
• 230000007012 clinical effect Effects 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 229940125758 compound 15 Drugs 0.000 description 1
• 229940126142 compound 16 Drugs 0.000 description 1
• 229940125810 compound 20 Drugs 0.000 description 1
• 229940126208 compound 22 Drugs 0.000 description 1
• 229940125833 compound 23 Drugs 0.000 description 1
• 229940127204 compound 29 Drugs 0.000 description 1
• 229940125878 compound 36 Drugs 0.000 description 1
• 229940125807 compound 37 Drugs 0.000 description 1
• 229940127573 compound 38 Drugs 0.000 description 1
• 229940125898 compound 5 Drugs 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 108010015417 connexin 36 Proteins 0.000 description 1
• 108010015404 connexin 38 Proteins 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 125000000753 cycloalkyl group Chemical group 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• 229960003067 cystine Drugs 0.000 description 1
• LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 230000030609 dephosphorylation Effects 0.000 description 1
• 238000006209 dephosphorylation reaction Methods 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
• 229960002986 dinoprostone Drugs 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 208000032625 disorder of ear Diseases 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 230000008846 dynamic interplay Effects 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 238000001493 electron microscopy Methods 0.000 description 1
• 238000003372 electrophysiological method Methods 0.000 description 1
• 238000002001 electrophysiology Methods 0.000 description 1
• 230000007831 electrophysiology Effects 0.000 description 1
• 210000002308 embryonic cell Anatomy 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• PJWPNDMDCLXCOM-UHFFFAOYSA-N encainide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1CCC1N(C)CCCC1 PJWPNDMDCLXCOM-UHFFFAOYSA-N 0.000 description 1
• 229960001142 encainide Drugs 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 102000015694 estrogen receptors Human genes 0.000 description 1
• 108010038795 estrogen receptors Proteins 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 210000001105 femoral artery Anatomy 0.000 description 1
• 210000003191 femoral vein Anatomy 0.000 description 1
• 210000002436 femur neck Anatomy 0.000 description 1
• 230000035558 fertility Effects 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 230000002600 fibrillogenic effect Effects 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 239000007888 film coating Substances 0.000 description 1
• 238000009501 film coating Methods 0.000 description 1
• 230000004907 flux Effects 0.000 description 1
• 210000000245 forearm Anatomy 0.000 description 1
• 210000003194 forelimb Anatomy 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• VPSRLGDRGCKUTK-UHFFFAOYSA-N fura-2-acetoxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=CC2=C1OC(C=1OC(=CN=1)C(=O)OCOC(C)=O)=C2 VPSRLGDRGCKUTK-UHFFFAOYSA-N 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000012224 gene deletion Methods 0.000 description 1
• 230000004077 genetic alteration Effects 0.000 description 1
• 231100000118 genetic alteration Toxicity 0.000 description 1
• 230000007277 glial cell activation Effects 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229940074045 glyceryl distearate Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 150000002332 glycine derivatives Chemical class 0.000 description 1
• VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
• XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
• 230000002710 gonadal effect Effects 0.000 description 1
• 210000001126 granulation tissue Anatomy 0.000 description 1
• JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
• BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
• 229960003132 halothane Drugs 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 230000000004 hemodynamic effect Effects 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• UFFSXJKVKBQEHC-UHFFFAOYSA-N heptafluorobutyric anhydride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(=O)OC(=O)C(F)(F)C(F)(F)C(F)(F)F UFFSXJKVKBQEHC-UHFFFAOYSA-N 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 108091008039 hormone receptors Proteins 0.000 description 1
• 210000002758 humerus Anatomy 0.000 description 1
• 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
• 125000001183 hydrocarbyl group Chemical group 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 150000001261 hydroxy acids Chemical class 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 230000002102 hyperpolarization Effects 0.000 description 1
• 208000015210 hypertensive heart disease Diseases 0.000 description 1
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical group O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 238000005286 illumination Methods 0.000 description 1
• 210000004713 immature microglia Anatomy 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
• 239000002917 insecticide Substances 0.000 description 1
• 230000003914 insulin secretion Effects 0.000 description 1
• 206010022498 insulinoma Diseases 0.000 description 1
• 229940056984 integrilin Drugs 0.000 description 1
• 210000004692 intercellular junction Anatomy 0.000 description 1
• 230000008776 intercellular pathway Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 230000010262 intracellular communication Effects 0.000 description 1
• 230000037041 intracellular level Effects 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 230000010189 intracellular transport Effects 0.000 description 1
• 238000010988 intraclass correlation coefficient Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 150000002513 isocyanates Chemical class 0.000 description 1
• 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
• SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 210000003644 lens cell Anatomy 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 238000005567 liquid scintillation counting Methods 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 230000007257 malfunction Effects 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 235000000824 malnutrition Nutrition 0.000 description 1
• 230000001071 malnutrition Effects 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 208000004840 megacolon Diseases 0.000 description 1
• IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
• 229960002237 metoprolol Drugs 0.000 description 1
• 230000002025 microglial effect Effects 0.000 description 1
• 230000001617 migratory effect Effects 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 150000004712 monophosphates Chemical class 0.000 description 1
• 230000001002 morphogenetic effect Effects 0.000 description 1
• 239000004570 mortar (masonry) Substances 0.000 description 1
• 230000003387 muscular Effects 0.000 description 1
• 210000000107 myocyte Anatomy 0.000 description 1
• 210000004457 myocytus nodalis Anatomy 0.000 description 1
• 230000002632 myometrial effect Effects 0.000 description 1
• 210000001087 myotubule Anatomy 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• 230000010004 neural pathway Effects 0.000 description 1
• 210000003757 neuroblast Anatomy 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000006576 neuronal survival Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 125000006501 nitrophenyl group Chemical group 0.000 description 1
• 238000001151 non-parametric statistical test Methods 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 208000015380 nutritional deficiency disease Diseases 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 230000008182 oocyte development Effects 0.000 description 1
• 230000034004 oogenesis Effects 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000004072 osteoblast differentiation Effects 0.000 description 1
• 210000004409 osteocyte Anatomy 0.000 description 1
• 208000005368 osteomalacia Diseases 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 230000003642 osteotropic effect Effects 0.000 description 1
• 229940127084 other anti-cancer agent Drugs 0.000 description 1
• 229960003343 ouabain Drugs 0.000 description 1
• 230000011599 ovarian follicle development Effects 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
• 229960001723 oxytocin Drugs 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 208000021255 pancreatic insulinoma Diseases 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 210000002990 parathyroid gland Anatomy 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 210000004197 pelvis Anatomy 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 229960003424 phenylacetic acid Drugs 0.000 description 1
• 239000003279 phenylacetic acid Substances 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 125000004344 phenylpropyl group Chemical group 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 208000014321 polymorphic ventricular tachycardia Diseases 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 235000003784 poor nutrition Nutrition 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 108020001213 potassium channel Proteins 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 208000024896 potassium deficiency disease Diseases 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 108090000468 progesterone receptors Proteins 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000001902 propagating effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
• 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 244000000040 protozoan parasite Species 0.000 description 1
• 230000000722 protumoral effect Effects 0.000 description 1
• 210000001147 pulmonary artery Anatomy 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 210000003742 purkinje fiber Anatomy 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 229940076788 pyruvate Drugs 0.000 description 1
• 238000000718 qrs complex Methods 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 239000000700 radioactive tracer Substances 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 239000012048 reactive intermediate Substances 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000029865 regulation of blood pressure Effects 0.000 description 1
• 230000030198 regulation of embryonic development Effects 0.000 description 1
• 230000018406 regulation of metabolic process Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000000250 revascularization Effects 0.000 description 1
• 208000007442 rickets Diseases 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• GFJRASPBQLDRRY-TWTQBQJDSA-N rotigaptide Chemical compound NC(=O)CNC(=O)[C@@H](C)NC(=O)CNC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@@H]1N(C(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(C)=O)CCC1 GFJRASPBQLDRRY-TWTQBQJDSA-N 0.000 description 1
• 229940043230 sarcosine Drugs 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000009758 senescence Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 230000008054 signal transmission Effects 0.000 description 1
• 230000007727 signaling mechanism Effects 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 210000001626 skin fibroblast Anatomy 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 239000001540 sodium lactate Substances 0.000 description 1
• 235000011088 sodium lactate Nutrition 0.000 description 1
• 229940005581 sodium lactate Drugs 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical class [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 1
• 239000008279 sol Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 230000021595 spermatogenesis Effects 0.000 description 1
• 238000013112 stability test Methods 0.000 description 1
• 238000003153 stable transfection Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 239000012607 strong cation exchange resin Substances 0.000 description 1
• 125000003107 substituted aryl group Chemical group 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000010414 supernatant solution Substances 0.000 description 1
• 230000003319 supportive effect Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 230000003956 synaptic plasticity Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 230000003390 teratogenic effect Effects 0.000 description 1
• 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000005031 thiocyano group Chemical group S(C#N)* 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 210000000779 thoracic wall Anatomy 0.000 description 1
• 230000001732 thrombotic effect Effects 0.000 description 1
• DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
• 210000002303 tibia Anatomy 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 238000000825 ultraviolet detection Methods 0.000 description 1
• 210000001364 upper extremity Anatomy 0.000 description 1
• 210000005167 vascular cell Anatomy 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
• 230000002227 vasoactive effect Effects 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 230000000283 vasomotion Effects 0.000 description 1
• 230000001457 vasomotor Effects 0.000 description 1
• 229960001722 verapamil Drugs 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 235000019166 vitamin D Nutrition 0.000 description 1
• 239000011710 vitamin D Substances 0.000 description 1
• 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
• 229960005080 warfarin Drugs 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 210000002417 xiphoid bone Anatomy 0.000 description 1